UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

            Date of Report (date of earliest event reported): December 18, 2017

                               CEL-SCI CORPORATION
                     -------------------------------------
             (Exact name of Registrant as specified in its charter)

    Colorado                          001-11889              84-0916344
---------------------------      --------------------   -----------------------
(State or other jurisdiction    (Commission File No.)      (IRS Employer
of incorporation)                                        Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
               -------------------------------------------------
          (Address of principal executive offices, including Zip Code)


Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                          ----------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this
chapter.

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]


<PAGE>

Item 5.02.  Departure  of  Directors  or  Certain  Officers;  Election  of
            Directors; Appointment of Certain Officers; Compensatory
            Arrangements of Certain Officers.

     On December 18, 2017 CEL-SCI  Corporation  appointed  Robert  Watson to its
Board of Directors.

     Mr. Watson (age 60) has over 35 years of  experience  in the  healthcare IT
industry  as a CEO,  board  member and  advisor to  multiple  companies.  Having
participated  in over 75  acquisitions,  he has raised  nearly  $750,000,000  in
capital, completed three public offerings and successfully sold four companies.

     Since  July 2017 Mr.  Watson  has been the  President  of the  Preparedness
Technology  Division at EMSystems (a subsidiary of  Intermedix,  Inc.).  Between
2015 to 2017,  prior to his joining  EMSystems,  he was the  President and Chief
Growth  Officer  of  NantHealth,  and  between  2011 to 2015,  he was the CEO of
Streamline  Health.  Both  NantHealth  and  Streamline  Health are NASDAQ listed
companies.  He has held  executive  positions at numerous  other  healthcare  IT
companies.

     Mr.  Watson  holds  an MBA from  the  Wharton  School  of  Business  at the
University of Pennsylvania and a BA from Syracuse University.



                                       2
<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  December 20, 2017                  CEL-SCI CORPORATION



                                    By: /s/ Patricia B. Prichep
                                        --------------------------------------
                                       Patricia B. Prichep
                                       Senior Vice President of Operations










                                       3
[{"type": "8-K", "sequence": "1", "filename": "form8k502apptwatson12-17.txt", "description": "8-K APPOINT WATSON", "secsgml_size_bytes": 4486}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "171267783"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

            Date of Report (date of earliest event reported): December 18, 2017

                               CEL-SCI CORPORATION
                     -------------------------------------
             (Exact name of Registrant as specified in its charter)

    Colorado                          001-11889              84-0916344
---------------------------      --------------------   -----------------------
(State or other jurisdiction    (Commission File No.)      (IRS Employer
of incorporation)                                        Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
               -------------------------------------------------
          (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                          ----------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this
chapter.

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]
Item 5.02.  Departure  of  Directors  or  Certain  Officers;  Election  of
            Directors; Appointment of Certain Officers; Compensatory
            Arrangements of Certain Officers.

     On December 18, 2017 CEL-SCI  Corporation  appointed  Robert  Watson to its
Board of Directors.

     Mr. Watson (age 60) has over 35 years of  experience  in the  healthcare IT
industry  as a CEO,  board  member and  advisor to  multiple  companies.  Having
participated  in over 75  acquisitions,  he has raised  nearly  $750,000,000  in
capital, completed three public offerings and successfully sold four companies.

     Since  July 2017 Mr.  Watson  has been the  President  of the  Preparedness
Technology  Division at EMSystems (a subsidiary of  Intermedix,  Inc.).  Between
2015 to 2017,  prior to his joining  EMSystems,  he was the  President and Chief
Growth  Officer  of  NantHealth,  and  between  2011 to 2015,  he was the CEO of
Streamline  Health.  Both  NantHealth  and  Streamline  Health are NASDAQ listed
companies.  He has held  executive  positions at numerous  other  healthcare  IT
companies.

     Mr.  Watson  holds  an MBA from  the  Wharton  School  of  Business  at the
University of Pennsylvania and a BA from Syracuse University.

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  December 20, 2017                  CEL-SCI CORPORATION

                                    By: /s/ Patricia B. Prichep
                                        --------------------------------------
                                       Patricia B. Prichep
                                       Senior Vice President of Operations

                                       3